Investing.com - Financial Markets Worldwide

Ionis Pharma director Klein sells $1.68 million in shares

Published 05/09/2025, 02:10
Ionis Pharma director Klein sells $1.68 million in shares
IONS
1.44%

Director Joseph Klein III of IONIS PHARMACEUTICALS INC (NASDAQ:IONS) sold 28,000 shares of common stock on September 3, 2025, at a price of $60.0, for a total value of $1.68 million. The sales were executed under a Rule 10b5-1 trading plan adopted on January 3, 2024. The transaction comes as IONS trades near its 52-week high of $62.08, with the stock showing remarkable strength, gaining 39.2% in the past week alone. According to InvestingPro analysis, the stock’s RSI suggests overbought conditions.

On the same day, Klein exercised options to acquire a total of 28,000 shares of IONIS PHARMACEUTICALS INC common stock through two transactions. The first transaction involved 12,000 shares at a price of $0.00, and the second transaction involved 16,000 shares at a price of $0.00.

Following these transactions, Klein directly holds 16,346 shares of IONIS PHARMACEUTICALS INC. Additionally, 100 shares are held by his son.

In other recent news, Ionis Pharmaceuticals has reported significant developments that have captured the attention of investors and analysts alike. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, showing substantial benefits in triglyceride lowering and a reduction in acute pancreatitis risk. This news prompted several analyst firms to adjust their outlooks on Ionis. RBC Capital raised its price target to $80, citing the potential of Ionis’s pancreatitis drug, while H.C. Wainwright increased its target to $95, noting strong triglyceride reductions in pivotal studies. BMO Capital upgraded Ionis’s stock rating to Outperform, expressing optimism about the blockbuster potential of Olezarsen. Additionally, Oppenheimer adjusted its price target to $81 following the positive trial outcomes. These developments underscore the growing confidence in Ionis’s therapeutic pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.